Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Bhupender S Chhikara & Keykavous Parang. (2010) Development of cytarabine prodrugs and delivery systems for leukemia treatment. Expert Opinion on Drug Delivery 7:12, pages 1399-1414.
Read now
Read now
Saad Akhtar, Amr El Weshi, Mohemmed Rahal, Yasser Khafaga, Abdelghani Tbakhi, Hind Humaidan & Irfan Maghfoor. (2008) Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: A single institution result of 168 patients. Leukemia & Lymphoma 49:4, pages 769-778.
Read now
Read now
Articles from other publishers (14)
Daisuke Koyama, Satoshi Nishiwaki, Yasuhiko Harada, Satomi Yamamoto, Shingo Kurahashi, Takumi Sugimoto, Toshihiro Iwasaki & Isamu Sugiura. (2017) Effective chemomobilization with etoposide and cytarabine (EC regimen) in lymphoma patients: a single-center, retrospective, observational study. Japanese Journal of Clinical Oncology 47:9, pages 820-825.
Crossref
Crossref
Jorge Labrador, M?nica Cabrero-Calvo, Estefan?a P?rez-L?pez, Mar?a Victoria Mateos, Lourdes V?zquez, Mar?a Dolores Caballero & Ram?n Garc?a-Sanz. (2014) ESHAP as salvage therapy for relapsed or refractory Hodgkin?s lymphoma. Annals of Hematology 93:10, pages 1745-1753.
Crossref
Crossref
Juan Montoro, Giovanna Andreola, Angelo Gardellini, Aleksandra Babic, Mara Negri, Niccol? Frungillo, Giovanni Martinelli & Daniele Laszlo. (2014) R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma. Transfusion and Apheresis Science 50:3, pages 411-414.
Crossref
Crossref
J.A. Cancelas. (2011) On how Rac controls hematopoietic stem cell activity. Transfusion 51:s4.
Crossref
Crossref
Jin-Hwang Liu, Chih-Cheng Chen, Li-Yen Bai, Shu-Chauo Chao, Mu-Shin Chang & Jeong-Shi Lin. (2008) Predictors for Successful Mobilization of Peripheral Blood Progenitor Cells with ESHAP+G-CSF in Patients with Pretreated Non-Hodgkin's Lymphoma. Journal of the Chinese Medical Association 71:6, pages 279-285.
Crossref
Crossref
Jose A. Cancelas, Michael Jansen & David A. Williams. (2006) The role of chemokine activation of Rac GTPases in hematopoietic stem cell marrow homing, retention, and peripheral mobilization. Experimental Hematology 34:8, pages 976-985.
Crossref
Crossref
S Akhtar, A Tbakhi, H Humaidan, A El Weshi, M Rahal & I Maghfoor. (2006) ESHAP+fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplantation 37:3, pages 277-282.
Crossref
Crossref
J-L Lee, S Kim, S W Kim, E-K Kim, S-B Kim, Y-K Kang, J Lee, M W Kim, C J Park, H-S Chi, J Huh, S-H Kim & C Suh. (2005) ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Bone Marrow Transplantation 35:5, pages 449-454.
Crossref
Crossref
Judith Ng‐Cashin & Thomas Shea. 2003. Thomas' Hematopoietic Cell Transplantation. Thomas' Hematopoietic Cell Transplantation
576
587
.
Evelyne Tuong EdwardsDominic A. SolimandoJr.Jr. & J. Aubrey Waddell. (2017) Etoposide, Methylprednisolone, Cytarabine, and Cisplatin (ESHAP) Regimen for Refractory or Relapsed Lymphomas. Hospital Pharmacy 37:3, pages 232-236.
Crossref
Crossref
Christos Emmanouilides, Mary Territo, Jeffrey Andrey & James Mason. (2001) A Randomized Phase II Study of Amifostine Used As Stem Cell Protectant in Non-Hodgkin Lymphoma Patients Receiving Cisplatin-Based Salvage Chemotherapy Prior to Stem Cell Transplant. Journal of Hematotherapy & Stem Cell Research 10:6, pages 887-893.
Crossref
Crossref
M Magagnoli, B Sarina, M Balzarotti, L Castagna, I Timofeeva, A Nozza, A Bertuzzi, L Siracusano, M Sinnone & A Santoro. (2001) Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma. Bone Marrow Transplantation 28:10, pages 923-927.
Crossref
Crossref
Theresa Hahn, Steven N. Wolff, Myron Czuczman, Richard I. Fisher, Hillard M. Lazarus, Julie Vose, Lisa Warren, Richard Watt & Philip L. McCartbyJr.Jr.. (2001) The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: An evidence-based review. Biology of Blood and Marrow Transplantation 7:6, pages 308-331.
Crossref
Crossref
Tanin Intragumtornchai, Wichai Prayoonwiwat, Tontanai Numbenjapon, Noppadol Assawametha, Rutchanee O'Charoen & Daratana Swasdikul. (2000) CHOP Versus CHOP Plus ESHAP and High-Dose Therapy with Autologous Peripheral Blood Progenitor Cell Transplantation for High-Intermediate?Risk and High-Risk Aggressive Non-Hodgkin's Lymphoma. Clinical Lymphoma 1:3, pages 219-225.
Crossref
Crossref